<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62065">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01888536</url>
  </required_header>
  <id_info>
    <org_study_id>YJ7-401</org_study_id>
    <nct_id>NCT01888536</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Efficacy of 『Opast Tablet』for Neurologic Claudication in Patients With Lumbar Spinal Stenosis</brief_title>
  <official_title>A Randomized, Double-Blind, Comparative, Multi-Center, Phase Ⅳ Clinical Trial to Evaluate Efficacy of 『Opast Tablet』for Neurologic Claudication in Patients With Lumbar Spinal Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yungjin Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yungjin Pharm. Co., Ltd.</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a comparative study of Opast tablet and Rikalin capsule 75mg and Rikalin
      capsule 75mg in combination with Opast tablet to evaluate improvement effectiveness of Opast
      tablet on subjective symptoms and neurologic claudication in patients with lumbar spinal
      stenosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects who provided written consents voluntarily after receiving a sufficient explanation
      about this trial will be assigned to one of groups(study group; limaprost, comparative group
      1; pregabalin, comparative group 2; limaprost+ pregabalin) by randomization at the rate of
      1:1:1.

      Subjects will take assigned investigational drugs thrice a day for eight weeks by
      double-blind and double-dummy methods, and they will visit the site two times at intervals
      of four weeks.

      At each site visit point, the improvement effectiveness will be comparatively evaluated by
      evaluation of following endpoints;

      Efficacy endpoints: ICD(initial claudication distance) at treadmill test (speed:3km/hr,
      grade:0%), VAS in pain on lower extremities, EQ-5D and ODI Safety endpoints: Vital signs,
      hematology/blood chemistry tests and adverse events, etc.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Initial Claudication Distance(ICD) on treadmill test</measure>
    <time_frame>up to 8 weeks after first administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>: Improvement of ICD at 8 weeks after first administration compared to                baseline, between study group(limaprost) and comparative group1(pregabalin)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Initial Claudication Distance(ICD) on treadmill test</measure>
    <time_frame>4 and 8 weeks after first administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Improvement of ICD at 4 weeks after first administration compared to             baseline, between study group(limaprost) and comparative group1(pregabalin)
Improvement of ICD at 4, 8 weeks after first administration compared to          baseline, between study group(limaprost) and comparative group 2(limaprost+       pregabalin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lower extremity pain score measured by Visual Analog Scale(VAS) 10cm</measure>
    <time_frame>4 and 8 weeks after first administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in VAS at 4, 8 weeks after first administration compared to               baseline, between study group(limaprost) and comparative group1(pregabalin)
Change in VAS at 4, 8 weeks after first administration compared to               baseline, between study group(limaprost) and comparative group 2(limaprost+       pregabalin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean ratio of change in score of EuroQuol 5D (EQ-5D)</measure>
    <time_frame>4 and 8 weeks after first administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in EQ-5D at 4, 8 weeks after first administration compared to            baseline, between study group(limaprost) and comparative group1(pregabalin)
Change in EQ-5D at 4, 8 weeks after first administration compared to            baseline, between study group(limaprost) and comparative group 2(limaprost+       pregabalin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean ratio of change in score of Oswestry Disability Index(ODI)</measure>
    <time_frame>4 and 8 weeks after first administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in ODI at 4, 8 weeks after first administration compared to               baseline, between study group(limaprost) and comparative group1(pregabalin)
Change in ODI at 4, 8 weeks after first administration compared to               baseline, between study group(limaprost) and comparative group 2(limaprost+       pregabalin)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Neurologic Claudication in Patients With Lumbar Spinal Stenosis</condition>
  <arm_group>
    <arm_group_label>Limaprost &amp; Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Limaprost 5㎍ tablet and a capsule of Pegabalin-Placebo thrice a day for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregabalin &amp; Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pregabalin 75mg capsule and a tablet of Limaprost-Placebo thrice a day for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Limaprost+Pregabalin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Limaprost 5㎍ tablet and Pregabalin 75mg capsule thrice a day for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Limaprost</intervention_name>
    <arm_group_label>Limaprost &amp; Placebo</arm_group_label>
    <arm_group_label>Limaprost+Pregabalin</arm_group_label>
    <other_name>Opast tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <arm_group_label>Pregabalin &amp; Placebo</arm_group_label>
    <arm_group_label>Limaprost+Pregabalin</arm_group_label>
    <other_name>Rikalin capsule 75mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo(for Pregabalin)</intervention_name>
    <description>mimic Pregabalin 75mg capsule</description>
    <arm_group_label>Limaprost &amp; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo(for Limaprost)</intervention_name>
    <description>mimic Limaprost tablet</description>
    <arm_group_label>Pregabalin &amp; Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is fully understand the clinical trial and obtained informed consent.

          -  Age 20-75years.

          -  Patients with a confirmed diagnosis of waist of spinal canal stenosis.

          -  Limb pain caused by waist of spinal canal stenosis index of VAS 3 or more patients.

          -  Subject who has numbness symptom on lower extremity(ies) and intermittent
             claudication that are due to spinal canal stenosis and fulfills both of    following
             criteria at the same time

               -  When screening visit, a medical examination by interview had the following
                  symptoms in subjects ; In daily life walking, when walked by within 20 minutes
                  on flatland, the subject can feel the symptoms (numbness, pain or tightness on
                  lower extremity(ies), etc.)

                    -  Subject who experienced numbness, pain, tightness or other similar
                       symptom(s) on lower extremity within 15 minutes from test start at
                       baseline(D1) evaluation.

                         -  speed: 3km/hr, grade:0%, posture: should keep their lumbar spinal
                            extended

        Exclusion Criteria:

          -  Pregnant or lactating women of childbearing potential not employing          adequate
             contraception.

          -  Patients who have the hereditary problem of galactose intolerance, Lapp lactase
             deficiency or grape sugar-galactose absorption defect.

          -  Patients with systemic disease affecting the lower limbs.

          -  Patients who have cauda equina syndrome.

          -  Patients with acute osteoporosis compression fracture in lumbar vertebra.

          -  Patients who have gait disturbance of degenerative arthritis by hip joint, knee
             joint, ankle joint.

          -  At least one month before the start of the study, patients use of steroid drug except
             lumbar dura mater.

          -  6 month before the start of the study, patients with ischaemic disease in     blood
             vessel, lung or the coronary artery,  varicose artery.

          -  Patients with lumbar necrosis in head of femur avascular necrosis, necrotic foot
             ulcer.

          -  Patients surgery by lumbar fusion and lumbar decompression.

          -  Patients with renal disease or need to hemodialysis.

               -  serum creatinine &gt; 2xUNL

          -  3 month before the start of the study, patients participated in another clinical
             research.

          -  Patients with difficult understanding spirit incompetence, lack of will or language
             barrier.

          -  The investigator judged seriously ill patients need surgery patient.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seong-Hwan Moon, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University College of Medicine Severance Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin Hyok Kim, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jae Hyup Lee, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>SMG-SNU Boramae Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Suk Kyung Soo, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyunghee University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ho Joong Kim, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ye Soo Park, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hanyang University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Moon Soo Park, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hallym University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seong-Hwan Moon, M.D.,Ph.D</last_name>
    <phone>82-2-2228-2188</phone>
    <email>shmoon@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>431-070</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moon Soo Park, M.D.,Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Moon Soo Park, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hanyang University Guri Hospital</name>
      <address>
        <city>Guri-si</city>
        <state>Gyeonggi-do</state>
        <zip>471-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ye Soo Park, M.D.,Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Ye Soo Park, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ho Joong Kim, M.D.,Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Ho Joong Kim, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KyungHee University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>130-872</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suk Kyung Soo, M.D.,Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Suk Kyung Soo, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inje University Sanggye Paik Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>139-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Hyok Kim, M.D.,Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Jin Hyok Kim, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae Hyup Kim, M.D.,Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Jae Hyup Lee, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seong-Hwan Moon, M.D.,Ph.D</last_name>
      <email>shmoon@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Seong Hwan Moon, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 26, 2013</lastchanged_date>
  <firstreceived_date>June 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Spinal Stenosis</mesh_term>
    <mesh_term>Intermittent Claudication</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
